

## Regimen Reference Order

### MYEL – D-CBD (SUBCUTANEOUS daratumumab injection)

ARIA: MYEL - [D-CBD (SUBCUT)]

Planned Course: Every 28 days until disease progression or unacceptable toxicity

Indication for Use: Multiple Myeloma Transplant Ineligible

CVAD: At Provider's Discretion

**Proceed with treatment if:**

**Day 1 ONLY**

**ANC equal to or greater than  $1 \times 10^9/L$  AND Platelets equal to or greater than  $75 \times 10^9/L$**

❖ **Contact Hematologist if parameters not met**

### SEQUENCE OF MEDICATION ADMINISTRATION

#### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Instruct patient to start vigorous oral pre-hydration (600-900 mL) the morning of cyclophosphamide treatment (Self-administered at home)		

#### Treatment Regimen

### MYEL – D-CBD (SUBCUTANEOUS daratumumab injection)

Establish primary solution 500 mL of: normal saline		
Drug	Dose	CCMB Administration Guideline
<b>Cycle 1</b>		
cetirizine	10 mg	Orally <b>1 hour</b> prior to daratumumab on <b>Days 1, 8, 15 and 22</b>
acetaminophen	975 mg	Orally <b>1 hour</b> prior to daratumumab on <b>Days 1, 8, 15 and 22</b>
montelukast	10 mg	Orally <b>1 hour</b> prior to daratumumab on <b>Day 1 ONLY</b>
dexamethasone	20 mg	<b>Day 1</b> IV in normal saline 50 mL over 15 minutes <b>1 hour</b> prior to daratumumab <i>*Nursing Alert: daratumumab starts 1 hour after completion of dexamethasone</i>
		<b>Days 8, 15 and 22</b> Orally <b>1 hour</b> prior to daratumumab
bortezomib	1.5 mg/m <sup>2</sup>	Subcutaneous injection once weekly on <b>Days 1, 8, 15 and 22</b>
<b>If applicable, wait 1 hour after completion of IV pre-medication(s) before starting daratumumab</b>		

daratumumab (Subcutaneous)	1800 mg (1800 mg = 15 mL)	<b>Subcutaneous:</b> Administer over 3 to 5 minutes into abdomen on <b>Days 1, 8, 15 and 22</b> Remove vial from refrigerator 30 minutes prior to preparing dose to bring to ambient temperature (15°C to 30°C) Use 23G needle <i>*Nursing Alert: Ensure subcutaneous daratumumab formulation is used (daratumumab-hyaluronidase)</i>
cyclophosphamide	300 mg/m <sup>2</sup>	Orally once daily in the morning on <b>Days 1, 8, 15 and 22</b> Take with or without food. Swallow whole <b>(Self-administered at home)</b>
dexamethasone	20 mg	Orally once daily in the morning with food on <b>Days 2, 9, 16 and 23</b> <b>(Self-administered at home)</b>
<b>Cycle 2</b>		
dexamethasone	40 mg	Orally once daily in the morning with food on <b>Days 1, 8, 15 and 22</b> <b>(Self-administered at home)</b>
cetirizine	10 mg	Orally 30 minutes prior to daratumumab on <b>Days 1, 8, 15 and 22</b>
acetaminophen	975 mg	Orally 30 minutes prior to daratumumab on <b>Days 1, 8, 15 and 22</b>
bortezomib	1.5 mg/m <sup>2</sup>	Subcutaneous injection once weekly on <b>Days 1, 8, 15 and 22</b>
daratumumab (Subcutaneous)	1800 mg (1800 mg = 15 mL)	<b>Subcutaneous:</b> Administer over 3 to 5 minutes into abdomen on <b>Days 1, 8, 15 and 22</b> Remove vial from refrigerator 30 minutes prior to preparing dose to bring to ambient temperature (15°C to 30°C) Use 23G needle <i>*Nursing Alert: Ensure subcutaneous daratumumab formulation is used (daratumumab-hyaluronidase)</i>
cyclophosphamide	300 mg/m <sup>2</sup>	Orally once daily in the morning on <b>Days 1, 8, 15 and 22</b> Take with or without food. Swallow whole <b>(Self-administered at home)</b>
<b>Cycles 3 to 6</b>		
dexamethasone	40 mg	Orally once daily in the morning with food on <b>Days 1, 8, 15 and 22</b> <b>(Self-administered at home)</b>
cetirizine	10 mg	Orally 30 minutes prior to daratumumab on <b>Days 1 and 15</b>
acetaminophen	975 mg	Orally 30 minutes prior to daratumumab on <b>Days 1 and 15</b>
bortezomib	1.5 mg/m <sup>2</sup>	Subcutaneous injection once weekly on <b>Days 1, 8, 15 and 22</b>
daratumumab (Subcutaneous)	1800 mg (1800 mg = 15 mL)	<b>Subcutaneous:</b> Administer over 3 to 5 minutes into abdomen on <b>Days 1 and 15</b> Remove vial from refrigerator 30 minutes prior to preparing dose to bring to ambient temperature (15°C to 30°C) Use 23G needle <i>*Nursing Alert: Ensure subcutaneous daratumumab formulation is used (daratumumab-hyaluronidase)</i>

cyclophosphamide	300 mg/m <sup>2</sup>	Orally once daily in the morning on <b>Days 1, 8, 15 and 22</b> Take with or without food. Swallow whole <b>(Self-administered at home)</b>
<b>Cycles 7 and 8</b>		
dexamethasone	40 mg	Orally once daily in the morning with food on <b>Days 1, 8, 15 and 22</b> <b>(Self-administered at home)</b>
cetirizine	10 mg	Orally 30 minutes prior to daratumumab on <b>Day 1</b>
acetaminophen	975 mg	Orally 30 minutes prior to daratumumab on <b>Day 1</b>
bortezomib	1.5 mg/m <sup>2</sup>	Subcutaneous injection once weekly on <b>Days 1, 8, 15 and 22</b>
daratumumab (Subcutaneous)	1800 mg (1800 mg = 15 mL)	<b>Subcutaneous:</b> Administer over 3 to 5 minutes into abdomen on <b>Day 1</b> Remove vial from refrigerator 30 minutes prior to preparing dose to bring to ambient temperature (15°C to 30°C) Use 23G needle <i>*Nursing Alert: Ensure subcutaneous daratumumab formulation is used (daratumumab-hyaluronidase)</i>
cyclophosphamide	300 mg/m <sup>2</sup>	Orally once daily in the morning on <b>Days 1, 8, 15 and 22</b> Take with or without food. Swallow whole <b>(Self-administered at home)</b>
<b>Cycle 9* and Onwards</b>		
cetirizine	10 mg	Orally 30 minutes prior to daratumumab on <b>Day 1</b>
acetaminophen	975 mg	Orally 30 minutes prior to daratumumab on <b>Day 1</b>
dexamethasone	20 mg	Orally 30 minutes prior to daratumumab on <b>Day 1</b>
daratumumab (Subcutaneous)	1800 mg (1800 mg = 15 mL)	<b>Subcutaneous:</b> Administer over 3 to 5 minutes into abdomen on <b>Day 1</b> Remove vial from refrigerator 30 minutes prior to preparing dose to bring to ambient temperature (15°C to 30°C) Use 23G needle <i>*Nursing Alert: Ensure subcutaneous daratumumab formulation is used (daratumumab-hyaluronidase)</i>
<b>* At physician's discretion, bortezomib may be prescribed Cycle 9 and onwards as maintenance on Days 1 and 15</b>		
cyclophosphamide (PROCYTOX®) available dosage strengths: 25 mg and 50 mg tablets Classification: Cytotoxic, Hazardous		

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

## REQUIRED MONITORING

### Baseline

- RBC serology (genotyping) mandatory prior to starting daratumumab
- Hepatitis B serology

### All Cycles

#### Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, albumin and glucose as per Physician Orders
- Serum Protein Electrophoresis (SPEP)/Free Light Chain Ratio (FLCH) (response assessment)

#### Days 8, 15 and 22

- No blood work required

### daratumumab (subcutaneous injection) monitoring

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O<sub>2</sub> saturation) at baseline and as clinically indicated
- No observation period is required after subcutaneous daratumumab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

## Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
valACYclovir	500 mg	Orally once daily
fluticasone and salmeterol combination	100 mcg – 50 mcg per dose	Prescribed at physician's discretion If patient has a history of asthma or COPD, 1 inhalation twice daily only as needed post daratumumab injection
<b>Cycles 1 to 8 only</b>		
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

## DISCHARGE INSTRUCTIONS

### All Cycles

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Remind patient to take recommended support medications at home

### Cycles 1 to 8

- Instruct patient to take dexamethasone and cyclophosphamide at home in the morning, as they are both part of the cancer therapy in this treatment regimen
- Instruct patient to:
  - Maintain oral intake of 2000 mL (8 glasses) of fluid daily at home
  - Empty bladder every 2 hours while awake and at bedtime for 24 hours after each dose of cyclophosphamide
  - Obtain immediate assistance as per your clinic's contact instructions if:
    - Symptoms of hemorrhagic cystitis (e.g. dysuria, hematuria)
    - Unable to drink recommended amount of fluid
- bortezomib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Advise patient to avoid green tea to prevent interactions with bortezomib
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade), and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

---

## ADDITIONAL INFORMATION

---

- daratumumab interferes with cross-matching and red blood cell antibody screening. **Indicate on all Canadian Blood Services requisitions that the patient is on daratumumab**
- daratumumab may interfere with the interpretation of the Serum Protein Electrophoresis (SPEP) results. **Indicate on all immunology (SPEP) requisitions that the patient is on daratumumab**
- Administering nurse must document any infusion-related reactions with any dose of daratumumab
- Consideration may be given to reducing dexamethasone dose at the physician's discretion to 20 mg for patients older than 75 years or who have a body mass index of less than 18.5 kg/m<sup>2</sup>
- valACYclovir (shingles prophylaxis) continues while on treatment and for 1 month after discontinuation of treatment due to risk of prolonged immunosuppression
- All patients should be considered for bisphosphonate therapy
- **Note: At Cycles 2 and 9, an entry called "Physician Reminder – dexamethasone dose evaluation" will appear in the electronic drug order. No action is required. This prompt is to remind the prescriber to evaluate the dexamethasone dose that begins at Cycles 2 and 9**